Acacia Senegal gum exudate offers protection against cyclophosphamide-induced urinary bladder cytotoxicity.
Cylophosphamide (CYCL) is a strong anticancer and immunosuppressive agent but its urotoxicity presents one of the major toxic effects that limit its wide usage particularly in high dose regimens. Therefore, this study aimed to investigate Acacia Senegal gum exudate ,Gum Arabic (GA), for its possible role as a natural, nontoxic agent against CYCL-induced urotoxicity. Male Swiss albino rats were exposed to CYCL (150 mg/kg BW, once i.p) with or without GA oral supplementation (7.5 g/kg/day for 6 days) through drinking water. Glutathione (GSH), Malondialdehyde (MDA) and Nitric oxide (NO) bladder contents were assessed. Responsiveness of the bladder rings to acetylcholine (ACh) in vitro, microscopic and macroscopic features are also investigated. CYCL produced pronounced harmful effects on bladder urothelial lining with significant increases in (MDA) and NO levels in the tissue homogenates. Bladder-GSH content is dropped by over 60% following CYCL injection. Bladder contractility, as measured by its responsiveness to ACh, recorded a marked reduction. The isolated bladders exhibited such macroscopic changes as severe edema, inflammation and extravasation. The bladder weight increased as well. Histological changes were evident in the form of severe congestion, petechial hemorrhage and chronic inflammatory reaction in the lamina propria accompanied with desquamated epithelia. GA, a potential protective agent, produced an almost complete reversal of NO induction, lipid peroxidation or cellular GSH bladder contents in the GA+CYCL-treated group. Likewise, bladder inflammation and edema were reduced. Bladder rings showed a remarkable recovery in their responsiveness to ACh. Bladder histological examination showed a near normal configuration and structural integrity, with a significant reduction in inflammation and disappearance of focal erosions. These remarkable effects of GA may be attributed to its ability to neutralize acrolein, the reactive metabolite of CYCL and/or the resultant reactive oxygen metabolites, through a scavenging action. GA may limit the cascading events of CYCL -induced damage, initiating a cytoprotective effect leading to structural and functional recovery of the bladder tissues.
Al-Yahya
Abdulaziz A
AA
Department of Pharmacology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Al-Majed
Abdulhakeem A
AA
Gado
Ali M
AM
Daba
Mohammad H
MH
Al-Shabanah
Othman A
OA
Abd-Allah
Adel R A
AR
D000109:Acetylcholine / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000633:toxicity*; D003520:Cyclophosphamide / Q000633:toxicity*; D003556:Cystitis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D004487:Edema / Q000209:etiology; D005978:Glutathione / Q000378:metabolism; D006170:Gum Arabic / Q000627:therapeutic use*; D007249:Inflammation / Q000209:etiology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D051381:Rats; D001743:Urinary Bladder / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology
D018906:Antineoplastic Agents, Alkylating; D009569:Nitric Oxide; D008315:Malondialdehyde; D003520:Cyclophosphamide; D006170:Gum Arabic; D005978:Glutathione; D000109:Acetylcholine